Skip to main content

Gout

      In abstract 0001 presented at ACR22 Convergence, researchers presented 12-month data from a randomized double-blind placebo-controlled trial of pegloticase with or without MTX.
      RT @JulianSegan: GWAS analysis of 2.5m people (120k with gout) showing identifies 1486 candidate causal genes for gout.

      Julian Segan JulianSegan

      2 years 7 months ago
      GWAS analysis of 2.5m people (120k with gout) showing identifies 1486 candidate causal genes for gout. Looking at urate handling as well as disease propagation (eg. IL1/6). Widespread GWAS allowing us to investigate these diseases differently. @RheumNow #ACR22 #Plenary
      RT @Janetbirdope: #ACR highlights - #pegloticase in #gout - less reactions and more benefit w #MTX MIRROR RCT. Better th

      Janet Pope Janetbirdope

      2 years 7 months ago
      #ACR highlights - #pegloticase in #gout - less reactions and more benefit w #MTX MIRROR RCT. Better than no MTX. Will change my practice - if I can access to a #peguricase, I will Rx w concomitant MTX Abst#0001 #ACR22 @RheumNow
      Sunday (Day 2): ACR 22 Daily Recap
      RT @RichardPAConway: Venuturupalli et al. Elevated CASPASE 1 expression in synovial biopsies of inter-critical gout sugg

      Richard Conway RichardPAConway

      2 years 7 months ago
      Venuturupalli et al. Elevated CASPASE 1 expression in synovial biopsies of inter-critical gout suggest ongoing NLRP3 inflammasome activity between gout attacks. @RheumNow #ACR22 Abstr#1808 https://t.co/OnJOpkRqH9 https://t.co/TGd6pn8Lne
      RT @RichardPAConway: Nair et al. HLA-B*5801 allele in African American gout patients. Present in 8%. Higher than expecte

      Richard Conway RichardPAConway

      2 years 7 months ago
      Nair et al. HLA-B*5801 allele in African American gout patients. Present in 8%. Higher than expected, ?need for screening pre-allopurinol? @RheumNow #ACR22 Abstr#1793 https://t.co/KrsjQ836BY https://t.co/bmPyqQi7OF
      RT @RichardPAConway: Hayashi et al. No effect of colchicine prophylaxis (vs NSAID or vs no prophylaxis) on MACE in re-an

      Richard Conway RichardPAConway

      2 years 7 months ago
      Hayashi et al. No effect of colchicine prophylaxis (vs NSAID or vs no prophylaxis) on MACE in re-analysis of CARES trial. @RheumNow #ACR22 Abstr#1809 https://t.co/I6evAl4BLd https://t.co/n70FvYah1p
      RT @RichardPAConway: Lin et al. Genetic risk (HR 2.3 women, 2.63 men) and lifestyle (HR 5.7 for women, 3.7 for men) both

      Richard Conway RichardPAConway

      2 years 7 months ago
      Lin et al. Genetic risk (HR 2.3 women, 2.63 men) and lifestyle (HR 5.7 for women, 3.7 for men) both individual contributors and synergistic (HR 9.1 women, 8.7 men) in gout development in both men and women. Modifiable! @RheumNow #ACR22 Abstr#1633 https://t.co/51KPgfXn1w https://t.co/gOU7DfOKvt
      RT @RichardPAConway: Helget et al. Subanalysis of STOP Gout. Allopurinol and febuxostat equal efficacy in CKD 3. More AK

      Richard Conway RichardPAConway

      2 years 7 months ago
      Helget et al. Subanalysis of STOP Gout. Allopurinol and febuxostat equal efficacy in CKD 3. More AKI with allopurinol 8.3% vs 2.4%. @RheumNow #ACR22 Abstr#1829 https://t.co/Z4JqYp4mTT https://t.co/xd8VGJVkNo
      RT @RichardPAConway: Khanna et al Transdermal NaHCO₃ in gout flare. N=98. Response rate D7 95% vs 79% (p=0.01). Lower

      Richard Conway RichardPAConway

      2 years 7 months ago
      Khanna et al Transdermal NaHCO₃ in gout flare. N=98. Response rate D7 95% vs 79% (p=0.01). Lower rescue med, 6% vs 20%. @RheumNow #ACR22 Abstr#1787 https://t.co/DWtlvjzBHw https://t.co/DOk993gCwz
      RT @RichardPAConway: Flood @FloodRachael et al. ULT reduces non-episodic foot pain in hyperuricaemic patients who fail t

      Richard Conway RichardPAConway

      2 years 7 months ago
      Flood @FloodRachael et al. ULT reduces non-episodic foot pain in hyperuricaemic patients who fail to meet gout classification criteria. Predicted by double counter or tophus on US. @RheumNow #ACR22 Abstr#1828 https://t.co/iOy0Vo5HVO https://t.co/vF98DFB7hJ
      RT @RichardPAConway: Johnson et al. VA matched cohort study. 560,000 gout patients, 5.4 million controls. Gout asoc with

      Richard Conway RichardPAConway

      2 years 7 months ago
      Johnson et al. VA matched cohort study. 560,000 gout patients, 5.4 million controls. Gout asoc with increased CV risk of 68% HF hospitalization, 25% HF-related death, 22% MACE. Poor SU control assoc CVD events. @RheumNow #ACR22 Abstr#1580 https://t.co/CBSMFRpg82 https://t.co/6IS3Cozjzs
      ×